Updated:
Noramco
Noramco, formerly a Johnson & Johnson division, supplies controlled-substance APIs to pharmaceutical manufacturers from its DEA-licensed US operations.
Noramco
Noramco is a pharmaceutical company founded in 1979 in Wilmington, Delaware. It develops and manufactures specialty active pharmaceutical ingredients, focusing on controlled substances. The company offers DEA-compliant security and production capacity for controlled substances, along with formulation-friendly particle size grades and technical packages.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Sector focus
Frequently asked questions
What does Noramco manufacture?
Noramco produces active pharmaceutical ingredients classified as controlled substances by the US Drug Enforcement Administration. Its portfolio includes opioid and stimulant APIs used in pain management and ADHD medications. The firm operates under strict DEA quota and licensing requirements, supplying pharmaceutical manufacturers who formulate and sell the finished drugs.
What is Noramco's relationship to Johnson & Johnson?
Noramco was originally the narcotics raw materials division within Johnson & Johnson. It was established as a standalone business, though the exact transaction and ownership structure after separation are matters of public record that remain less widely reported than the firm's operational history within J&J.
How does DEA regulation affect Noramco's operations?
As a manufacturer of Schedule II controlled substances, Noramco must adhere to annual production quotas set by the DEA, maintain secure supply-chain documentation, and operate facilities subject to federal inspection. This regulatory framework creates significant barriers to entry, limiting the number of competitors capable of producing commercial volumes of controlled-substance APIs.
Who are Noramco's customers?
Noramco supplies pharmaceutical companies, including generic drug manufacturers and branded pharmaceutical firms, that formulate controlled substances into finished-dose medications. Its APIs are the chemical starting point for widely dispensed prescriptions in pain management and psychiatric care, placing Noramco upstream in the pharmaceutical supply chain.
Is Noramco exposed to opioid litigation risk?
API manufacturers have faced scrutiny in broader opioid litigation, though liability has more commonly attached to finished-dose manufacturers, distributors, and dispensers. Noramco's regulatory compliance posture and role as an ingredient supplier position it differently than downstream opioid marketers, but the evolving legal landscape warrants ongoing monitoring by any allocator assessing the firm.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: